Since bortezomib was approved and clinically available for treatment of several malignant tumors, such as multiple myeloma and mantle cell lymphoma [34], we verified the therapeutic effectiveness of bortezomib treatment for cisplatin resistance caused by CYLD down-regulation in SAS cells. The gene discussed is CYLD; the disease is plasma cell myeloma.